Please login to the form below

Not currently logged in
Email:
Password:

ArchiMed acquires life sciences consultancy Deallus

Healthcare private equity firm is also looking at a number of 'bolt-on' deals

Deallus Claudio D'AmbrosioArchiMed, Europe's first independent private equity healthcare specialist, has acquired majority control of Deallus Consulting.

The financial details have not been published. The acquisition was the result of a proprietary process, with senior managers at Deallus reinvesting all proceeds from the deal into the group. 

ArchiMed is also reviewing a number of possible bolt-on acquisitions for Deallus, the former said in a statement. 

Deallus chief executive Claudio D'Ambrosio (pictured) said: “We are excited to work in partnership with ArchiMed and leverage their networks in both the consulting and healthcare industries to take Deallus into the next phase of its growth.”

He told PMLiVE: “While the operations of Deallus will remain largely intact, with the same people and processes, the partnership with ArchiMed expands the depth and breadth of our expertise. We now have an unparalleled global perspective that will be extremely useful in growing our services developing innovative approaches for clients to address markets needs around the world.

D'Ambrosio added that acquiring Deallus would enable ArchiMed to be more involved in pharma services.

He explained that the acquisition will have no implication for staff numbers at Deallus for the foreseeable future, although reviews will take place periodically. 

Asked whether the Deallus brand would change, D'Ambrosio told PMLiVE: “No. We'll remain Deallus. Our brand is very well known in North America, as is ArchiMed in Europe.”

“What we do see, though, is the market recognising that the two entities are now part of the same team.”

Global life sciences consultancy Deallus has a staff of 80 consultants with headquarters in London and offices in New York, Los Angeles, Princeton, Tokyo and Singapore.

Since its founding in 2004, Deallus's annual revenue growth has averaged at some 20% and turnover in the company's most recent fiscal year stood at £15m.

Robin Filmer-Wilson, a managing partner of ArchiMed, said:“Deallus does exactly what a specialist consultant should do, it inspires clients to develop best-in-class strategies through exceptionally deep market understanding and insight.

“We intend to accelerate the growth of Deallus by providing access to new accounts, aiding recruitment and helping to set up additional offices globally.”

Article by
Tara Craig

14th December 2015

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....